Johnson & Johnson (JNJ) PT Lowered to $175 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Johnson & Johnson's (JNJ) Potential to Change Multiple Myeloma Treatment Paradigm in Underappreciated, Stock Remains Top Pick - Cantor Fitzgerald
January 24, 2022 6:24 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $215.00 price target on Johnson & Johnson (NYSE: JNJ) in light of the upcoming PDUFA for the company's CAR-T therapy.
The analyst quotes: "The PDUFA date for Johnson and Johnson (JNJ) and Legend Biotech's BCMA (B-cell... More
